IRBs create delays for low‑risk research

Drug development has never been more expensive, in terms of output per dollar spent. 

This trend, called Eroom's law, is surprising, considering incredible technological advances.

Ben and Saloni talk to Ruxandra Teslo about why this has happened and what can be done about it.

How can we reform clinical trials to make them more efficient and abundant? Why are so many pharma companies moving early trials to Australia? What's wrong with ethics boards and how can we fix them without compromising on safety?